Biologics, an alternative therapeutic approach for oral lichen planus

Journal of Oral Pathology and Medicine

Volumn 40, Issue 7, 2011, Pages 521-524

  Zhang, Jing ^a   Zhou, Gang ^a   Du, Ge Fei ^a   Xu, Xue Yi ^a   Zhou, Hong Mei ^b  

^a WUHAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

Author keywords

Biologics; Oral lichen planus; Pathogenesis; T cells; Treatment

Indexed keywords

ADALIMUMAB; ALEFACEPT; BASILIXIMAB; BCG VACCINE; CD11 ANTIGEN; CD16 ANTIGEN; CD2 ANTIGEN; EFALIZUMAB; ETANERCEPT; GAMMA INTERFERON; IMMUNOMODULATING AGENT; INFLIXIMAB; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 4; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 3; MESSENGER RNA; POLYSACCHARIDE NUCLEIC ACID FRACTION OF BACILLUS CALMETTE GUERIN; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; UNCLASSIFIED DRUG;

ANTIGEN PRESENTING CELL; B LYMPHOCYTE; BIOLOGICAL THERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHILL; DISEASE SEVERITY; DIZZINESS; FEVER; HEADACHE; HUMAN; IMMUNOPATHOGENESIS; INFECTION; LICHEN PLANUS; LICHENOID; NAUSEA; PATHOGENESIS; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PSORIASIS; REVIEW; SWELLING; T LYMPHOCYTE; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ANTIBODIES, MONOCLONAL; AUTOIMMUNE DISEASES; BIOLOGICAL AGENTS; HUMANS; IMMUNOLOGIC FACTORS; LICHEN PLANUS, ORAL; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79960652041     PISSN: 09042512     EISSN: 16000714     Source Type: Journal    
DOI: 10.1111/j.1600-0714.2011.01029.x     Document Type: Review

References (42)

1. Scully C, Eisen D, Carrozzo M. Management of oral lichen planus. Am J Clin Dermatol 2000; 1: 287-306.
2. Lodi G, Scully C, Carrozzo M, Griffiths M, Sugerman PB, Thongprasom K. Current controversies in oral lichen planus: report of an international consensus meeting. Part 1. Viral infections and etiopathogenesis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2005; 100: 40-51.
3. Sugerman PB, Savage NW, Zhou X, Walsh LJ, Bigby M. Oral lichen planus. Clin Dermatol 2000; 18: 533-9.
4. Sugerman PB, Savage NW, Walsh LJ, et al. The pathogenesis of oral lichen planus. Crit Rev Oral Biol Med 2002; 13: 350-65.
5. Farhi D, Dupin N. Pathophysiology, etiologic factors, and clinical management of oral lichen planus, part I: facts and controversies. Clin Dermatol 2010; 28: 100-8.
6. Leonardi CL. Efalizumab: an overview. J Am Acad Dermatol 2003; 49: S98-104.
7. Sugerman PB, Satterwhite K, Bigby M. Auto-cytotoxic T cell clones in lichen planus. Br J Dermatol 2000; 142: 449-56.
8. Thongprasom K, Dhanuthai K. Steriods in the treatment of lichen planus: a review. J Oral Sci 2008; 50: 377-85.
9. Mollaoglu N. Oral lichen planus: a review. Br J Oral Maxillofac Surg 2000; 38: 370-7.
10. Levin C, Maibach HI. Topical corticosteroid-induced adrenocortical insufficiency: clinical implications. Am J Clin Dermatol 2002; 3: 141-7.
11. Foti C, Calogiuri G, Cassano N, Buquicchio R, Vena GA. Contact allergy to topical corticosteroids: update and review on cross-sensitization. Recent Pat Inflamm Allergy Drug Discov 2009; 3: 33-9.
12. Charmandari E, Kino T, Ichijo T, Chrousos GP. Generalized glucocorticoid resistance: clinical aspects, molecular mechanisms, and implications of a rare genetic disorder. J Clin Endocrinol Metab 2008; 93: 1563-72.
13. Carrozzo M, Thorpe R. Oral lichen planus: a review. Minerva Stomatol 2009; 58: 519-37.
14. Marchesseau-Merlin AS, Perea R, Kanold J, Demeocq F, Souteyrand P, D'Incan M. Photopheresis: an alternative therapeutic approach in corticoresistant erosive oral lichen planus. Ann Dermatol Venereol 2008; 135: 209-12.
15. Sivamani RK, Correa G, Ono Y, Bowen MP, Raychaudhuri SP, Maverakis E. Biological therapy of psoriasis. Indian J Dermatol 2010; 55: 161-70.
16. Shirota Y, Illei GG, Nikolov NP. Biologic treatments for systemic rheumatic diseases. Oral Dis 2008; 14: 206-16.
17. O'Neill ID. Guidance on the use of biological agents in the treatment of oral mucosal disease. Br J Dermatol 2010; 162: 1410-1.
18. O'Neill ID. Off-label use of biologicals in the management of inflammatory oral mucosal disease. J Oral Pathol Med 2008; 37: 575-81.
19. Sugiyama H, McCormick TS, Cooper KD, Korman NJ. Alefacept in the treatment of psoriasis. Clin Dermatol 2008; 26: 503-8.
20. Ellis CN, Krueger GG, Alefacept Clinical Study Group. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med 2001; 345: 248-55.
21. Fivenson DP, Mathes B. Treatment of generalized lichen planus with alefacept. Arch Dermatol 2006; 142: 151-2.
22. Chang AL, Badger J, Rehmus W, Kimball AB. Alefacept for erosive lichen planus: a case series. J Drugs Dermatol 2008; 7: 379-83.
23. Gisondi P, Girolomoni G. Biologic therapies in psoriasis: a new therapeutic approach. Autoimmun Rev 2007; 6: 515-9.
24. Lowes MA, Chamian F, Abello MV, et al. Increase in TNF-alpha and inducible nitricoxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a). Proc Natl Acad Sci USA 2005; 102: 19057-62.
25. Cheng A, Mann C. Oral erosive lichen planus treated with efalizumab. Arch Dermatol 2006; 142: 680-2.
26. Böhm M, Luger TA. Lichen planus responding to efalizumab. J Am Acad Dermatol 2007; 56(Suppl): S92-3.
27. Heffernan MP, Smith DI, Bentley D, Tabacchi M, Graves JE. A single-center, open-label, prospective pilot study of subcutaneous efalizumab for oral erosive lichen planus. J Drugs Dermatol 2007; 6: 310-4.
28. Korman BD, Tyler KL, Korman NJ. Progressive multifocal leukoencephalopathy, efalizumab, and immunosuppression: a cautionary tale for dermatologists. Arch Dermatol 2009; 145: 937-42.
29. Kipnis CD, Myers WA, Opeola M, Gottlieb AB. Biologic treatments for psoriasis. J Am Acad Dermatol 2005; 52: 671-82.
30. Sugermann PB, Savage NW, Seymour GJ, Walsh LJ. Is there a role for tumour necrosis factor-alpha (TNF-α) in oral lichen planus? J Oral Pathol Med 1996; 25: 219-24.
31. Simark-Mattsson C, Bergenholtz G, Jontell M, et al. Distribution of interleukin-2, -4, -10, tumour necrosis factor-α and transforming growth factor-βmRNAs in oral lichen planus. Arch Oral Biol 1999; 44: 499-507.
32. Yarom N. Etanercept for the management of oral lichen planus. Am J Clin Dermatol 2007; 8: 121.
33. Chao TJ. Adalimumab in the management of cutaneous and oral lichen planus. Cutis 2009; 84: 325-8.
34. Asarch A, Gottlieb AB, Lee J, et al. Lichen planus-like eruptions: an emerging side effect of tumor necrosis factor-alpha antagonists. J Am Acad Dermatol 2009; 61: 104-11.
35. Ferrer F, Machado S, Alves R, et al. Induction with basiliximab in renal transplantation. Transplant Proc 2010; 42: 467-70.
36. Rebora A, Parodi A, Murialdo G. Basiliximab is effective for erosive lichen planus. Arch Dermatol 2002; 138: 1100-1.
37. Giri PK, Schorey JS. Exosomes derived from M. bovis BCG infected macrophages activate antigen-specific CD4+ and CD8+ T cells in vitro and in vivo. PLoS ONE 2008; 3: e2461.
38. Zhou G, Fan MW, Liu JY. Regulation of BCG-polysaccharide nucleic acid on Thl/Th2 cytokines from peripheral blood mononuclear cells in oral lichen planus. Chin J Dent Res 2004; 7: 5-10.
39. Xiong C, Li Q, Lin M, et al. The efficacy of topical intralesional BCG-PSN injection in the treatment of erosive oral lichen planus: a randomized controlled trial. J Oral Pathol Med 2009; 38: 551-8.
40. Carr DR, Heffernan MP. Off-label uses of rituximab in dermatology. Dermatol Ther 2007; 20: 277-87.
41. Carr DR, Heffernan MP. Innovative uses of rituximab in dermatology. Dermatol Clin 2010; 28: 547-57.
42. Parmentier L, Bron BA, Prins C, Samson J, Masouyé I, Borradori L. Mucocutaneous lichen planus with esophageal involvement: successful treatment with an anti-CD20 monoclonal antibody. Arch Dermatol 2008; 144: 1427-30.